ClinicalTrials.gg

Program

Riboflavin

Also written as “riboflavin solution”, “Riboflavin 0.1% ophthalmic solution and pulsed light” and “Riboflavin 0.1% ophthalmic solution and non-pulsed light”.

Its studies are mostly in Keratoconus · Hyperopia · Dilatation, Pathologic · Corneal Ulcer · Fatigue, led by 4 companies.

Furthest: phase 3, since Apr 27, 201111 company-led studies, 1 open or runningNext primary completion: Dec 31, 2030 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Glaukos50 open or runningphase 3since Apr 27, 2011Apr 27, 2011none ahead
Price Vision Group41 open or runningphase 3since Apr 17, 2019May 30, 2009Dec 31, 2030phase 3 · NCT07841470
Nvision Laser Eye Centers10 open or runningphase 2since May 3, 2016May 3, 2016none ahead
Topcon10 open or runningphase 3since Jul 11, 2011Jul 11, 2011none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 30, 2009First study: no phase study in Corneal UlcerNew to Price Vision GroupPrice Vision Group · NCT00912509 · 30 enrolled · United States
  2. Jun 11, 2010Phase 2 study in KeratoconusPrice Vision Group · NCT01143389 · 510 enrolled · United States
  3. Apr 27, 2011Glaukos's first study: phase 3 study in KeratoconusNew to GlaukosGlaukos · NCT01344187 · 236 enrolled · United States
  4. Jul 11, 2011Topcon's first study: phase 3 study in KeratoconusNew to TopconTopcon · NCT01398852 · 500 enrolled · United States
  5. Jul 16, 20122 phase 3 studiesGlaukos · NCT01643252, NCT01643226
  6. Jun 28, 2013Phase 2 study in HyperopiaGlaukos · NCT01893359 · 2 enrolled · United States
  7. Oct 25, 2013Phase 3 study in KeratoconusGlaukos · NCT01972854 · 92 enrolled · United States
  8. May 3, 2016Nvision Laser Eye Centers's first study: phase 2 study in KeratoconusNew to Nvision Laser Eye CentersNvision Laser Eye Centers · NCT02762253 · 320 enrolled · United States
  9. Apr 17, 2019Phase 3 study in KeratoconusPrice Vision Group · NCT03922542 · 508 enrolled · United States
  10. Sep 19, 2026Phase 3 study in KeratoconusPrice Vision Group · NCT07841470 · 500 planned · United States

Ahead

  1. Dec 31, 2030Primary completion: phase 3 study in KeratoconusPrice Vision Group · NCT07841470

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07841470Keratoconus · United States3RecruitingPrice Vision GroupDec 31, 2030500
NCT03922542Keratoconus · United States3CompletedPrice Vision GroupJun 30, 2026508
NCT02762253Keratoconus · United States2TerminatedNvision Laser Eye CentersApr 2016320
NCT01972854Keratoconus · United States3TerminatedGlaukosMar 201692
NCT01893359Hyperopia · United States2TerminatedGlaukosFeb 20152
NCT01643252Corneal Ectasia3WithdrawnGlaukos0
NCT01643226Keratoconus · United States3CompletedGlaukosJul 2015230
NCT01398852Keratoconus · United States3TerminatedTopconJul 2012500
NCT01344187Keratoconus · United States3CompletedGlaukosJun 2015236
NCT01143389Keratoconus · United States2CompletedPrice Vision GroupMay 30, 2017510
NCT00912509Corneal Ulcer · United States–TerminatedPrice Vision GroupJun 201330

How it is read

Names in the registry

  • “riboflavin solution”, 3 entries
  • “Riboflavin”, 2 entries
  • “Riboflavin 0.1% ophthalmic solution and pulsed light”, 1 entry
  • “Riboflavin 0.1% ophthalmic solution and non-pulsed light”, 1 entry
  • “riboflavin 0.1%”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.